Lung diseases affect ~600M people worldwide. The total cost to the US economy exceeds $180B p.a., yet there is a profound lack of fast, easy point-of-care diagnostics. Our patented technology fills this gap, providing rapid, effortless lung function assessment and unique insights into diagnostically highly important "small airways". Our tremoFlo C-100 AOS is approved and selling in Europe, Canada and Australia. We expect our 510(k) in early 2016.